Key result
Abciximab adjunctive to primary PCI was associated with decreased 30-day re-infarction (0% vs 2.8%, P=0.003) but increased disabling stroke (2.3% vs 0.4%, P=0.019).
Why the study?
Does abciximab as adjunctive to pPCI improve ST-segment resolution and clinical outcomes in patients with acute myocardial infarction?
Cohort (n=790)
Yes
Does abciximab as adjunctive to pPCI improve ST-segment resolution and clinical outcomes in patients with acute myocardial infarction?
Absolute Event Rate: 0% vs 2.8%
p-value: p=0.003
In patients undergoing pPCI for acute myocardial infarction, adjunctive abciximab reduces re-infarction but increases the risk of disabling stroke, offsetting potential clinical benefits.
May offset re-infarction benefit via stroke risk; leaves open net effect of adjunctive abciximab in pPCI.
INTRODUCTION: Successful reperfusion at the epicardial level is not always accompanied by reperfusion of the microvasculature. Therapies targeted against 'no-flow' are often employed in patients receiving primary percutaneous coronary intervention (pPCI) after acute myocardial infarction. HYPOTHESIS: Abciximab as adjunctive to pPCI will improve ST-segment resolution used as a surrogate for optimal microvascular reperfusion, and improve prognosis. METHODS: In the DANAMI-2 trial 309/790 (39%) patients treated with pPCI received abciximab at physician discretion. SigmaST-segment elevation at baseline, 90 min, 4 h, 12 h, 24 h after pPCI and at discharge was measured and ST-segment resolution grouped as: Complete (> or = 70 %); Partial (> or = 30 to < 70%); No (< 30%). Clinical endpoints were death, re-infarction and disabling stroke. RESULTS: Abciximab prescription varied from 24.4-60.3% in the different hospitals. Patients receiving abciximab had a higher risk profile. ST-segment resolution at 90 min and 24 h was identical in the two groups, but at 4 h and 12 h partial ST-segment resolution was more pronounced in patients receiving abciximab (P = 0.001, P = 0.026). In a multivariate analysis, adjusting for baseline differences abciximab was associated with improved partial ST-segment resolution at 12 h. Patients treated with abciximab had no re-infarction at 30 days (0% versus 2.8%, P = 0.003), but increased disabling stroke rate (2.3% versus 0.4%; P = 0.019) driven by cerebral infarctions, and not intracranial hemorrhage. There were no differences in death rates. CONCLUSIONS: In the DANAMI-2 trial with no age limit, the decreased re-infarction rates in patients receiving abciximab was offset by increased disabling stroke rates. Abciximab in conjunction with pPCI is associated with more pronounced partial ST-segment resolution after 4 h to 12 h suggesting improved microvascular reperfusion.
No takes yet. Share an insight, caveat, or question.
Sejersten et al. (2006) conducted a cohort in Acute myocardial infarction (n=790). Abciximab vs. No abciximab was evaluated on Re-infarction at 30 days (p=0.003). Abciximab adjunctive to primary PCI was associated with decreased 30-day re-infarction (0% vs 2.8%, P=0.003) but increased disabling stroke (2.3% vs 0.4%, P=0.019).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: